ArticleFrontiers in immunology2026
Beyond eosinophil counts: organ involvement patterns across hypereosinophilic syndrome subtypes in a single-center cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypereosinophilic syndrome (HES) is defined by persistent hypereosinophilia Q5 associated with eosinophil-mediated organ damage. However, the relationship between HES etiology and organ-involvement patterns remains incompletely defined, particularly in non-hematological forms. This study aimed to describe organ involvement across HES subtypes and to explore clinical associations with multiorgan disease. Methods: In this retrospective single-center study, 105 patients referred for hypereosinophilia were classified after a standardized two-tailed diagnostic work-up as reactive HES, single-organ HES, lymphocytic-variant HES (L-HES), overlap HES, idiopathic HES, myeloid HES, or HEus. Demographic data, absolute eosinophil count (AEC) at onset, organ domains, organ burden, and exploratory associations with multiorgan disease were analyzed. Results: Mean age at onset was 54.6 ± 18.9 years, and 60.0% of patients were male. Thirteen patients were classified as HEus and had no detectable organ involvement, whereas all HES categories showed at least one involved organ domain. Among recorded organ domains, lung involvement was the most frequent (39.0%), followed by gastrointestinal (30.5%) and cutaneous involvement (29.5%). Peripheral nervous system involvement occurred in 19.0% of patients, whereas cardiac, renal, thrombotic, and central nervous system involvement occurred in 6.7%, 4.8%, 1.9%, and 1.0%, respectively. Multiorgan involvement occurred in 34 patients (32.4%). Discussion: Organ burden differed significantly across subtypes, with overlap HES, mainly driven by eosinophilic granulomatosis with polyangiitis (EGPA), showing the highest multiorgan burden. L-HES and idiopathic HES were predominantly associated with cutaneous disease, whereas single-organ HES involved only the gastrointestinal tract or lung. AEC correlated with the number of involved organs and was strongly associated with multiorgan involvement. Organ involvement in HES is common, heterogeneous, and unevenly distributed across subtypes. Integrating etiological classification with systematic organ phenotyping may improve risk stratification and guide diagnostic and follow-up strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.